Steven Cohen acquired 2.67 Million Immunovant shares worth $72.5 Million. That's 0.22% of their equity portfolio (145th largest holding). The investor owns 1.80% of the outstanding Immunovant stock. The first Immunovant trade was made in Q1 2020. Since then Steven Cohen bought shares six more times and sold shares on eight occasions. The investor's estimated purchase price is $98.1 Million, resulting in a loss of 26%.